{
    "clinical_study": {
        "@rank": "11732", 
        "acronym": "CMX001  Adv", 
        "arm_group": {
            "arm_group_label": "CMX001", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter study of Brincidofovir (CMX001) (BCV) administered twice weekly (BIW)\n      for the treatment of AdV infection detected during asymptomatic AdV viremia or during\n      symptomatic AdV infection. After completing a screening assessment to confirm study\n      eligibility, all enrolled subjects will undergo a treatment period of 12 weeks. Beginning on\n      Day 1, adult (\u2265 18 years) and adolescent (13-17 years) subjects weighing > 50 kg will\n      receive BCV 100 mg BIW; children up to 12 years of age will receive weight-based doses of 2\n      mg/kg BIW, not-to-exceed a total dose of 200 mg/week."
        }, 
        "brief_title": "Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection", 
        "condition": "Adenovirus Infection", 
        "condition_browse": {
            "mesh_term": "Adenoviridae Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have undergone hematopoietic cell transplant (HCT), solid organ\n             transplant (SOT)\n\n          -  Have a primary or other severe immunodeficiency which predisposes to rapid\n             progression to disseminated AdV disease\n\n          -  Must be able to ingest, absorb and tolerate oral medication\n\n          -  Willing and able to understand and provide written informed consent. For minors or\n             those incapable of providing written informed consent (i.e., incapacitated),\n             understood, written and informed consent must be provided by a parent or legal\n             guardian or representative.\n\n          -  To the best of his or her (or parent/guardian) knowledge, willing and able to\n             participate in all required study activities for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant or currently nursing.\n\n          -  Patients with any other condition that would, in the judgment of the investigator,\n             put the patient at increased risk during participation in the study, or interfere\n             with the conduct of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087306", 
            "org_study_id": "CMX001 304"
        }, 
        "intervention": {
            "arm_group_label": "CMX001", 
            "description": "CMX001 administered twice weekly, dose depending on weight.", 
            "intervention_name": "CMX001", 
            "intervention_type": "Drug", 
            "other_name": "Brincidofovir"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Adenovirus Infection", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "David Loeb, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27712"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Vinod Prasad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnatti", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnatti Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Grimley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "St. Jude Children's Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (Chimerix Study CMX001-304)", 
        "overall_contact": {
            "email": "clinicaltrials@chimerix.com", 
            "last_name": "Herve Mommeja-Marin, MD", 
            "phone": "919-806-1074"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the overall mortality at Week 24 of subjects treated with BCV during asymptomatic adenovirus (AdV) viremia or \"early\" AdV infection to the mortality at Week 24 for subjects treated with BCV during symptomatic or \"late\" AdV disease", 
            "measure": "To compare the overall mortality at Week 24 of subjects treated with BCV during asymptomatic adenovirus (AdV) viremia or \"early\" AdV infection to the mortality at Week 24 for subjects treated with BCV during symptomatic or \"late\" AdV disease", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chimerix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chimerix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}